stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) EBITDA
Arrowhead Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $116.5M, compared with −$585.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$204.6M. Over the past ten years it has ranged from −$585.7M (fiscal 2024) to $116.5M (fiscal 2025) — the current reading is the highest in ten years. Arrowhead Pharmaceuticals, Inc. ranks 511th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $116.5M | — |
| FY2024 | −$585.7M | — |
| FY2023 | −$194.5M | — |
| FY2022 | −$165.2M | — |
| FY2021 | −$140.5M | — |
| FY2020 | −$86.7M | — |
| FY2019 | $66.7M | — |
| FY2018 | −$50.9M | — |
| FY2017 | −$32.3M | — |
| FY2016 | −$78.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$164.3M | — |
| Mar 2026 | −$136.8M | — |
| Dec 2025 | $47.2M | (4.16%) |
| Sep 2025 | $49.2M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| CORT Corcept Therapeutics Incorporated compare | $108.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| ARWR Arrowhead Pharmaceuticals, Inc. | −$204.6M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement